Janus Kinase Inhibitors Modify the Fatty Acid Profile of Extracellular Vesicles and Modulate the Immune Response

Overview

Journal Heliyon

Specialty Social Sciences

Date 2024 Feb 5

PMID 38314280

Authors

Ana Maria Daza Zapata

Karen Alvarez

Gloria Vasquez Duque

Juliana Palacio

Mauricio Rojas Lopez

Affiliations

Soon will be listed here.

Abstract

Background: Janus kinase inhibitors (jakinibs) are immunomodulators used for treating malignancies, autoimmune diseases, and immunodeficiencies. However, they induce adverse effects such as thrombosis, lymphocytosis, and neutropenia that could be mediated by extracellular vesicles (EVs). These particles are cell membrane-derived structures that transport cellular and environmental molecules and participate in intercellular communication. Jakinibs can modify the content of EVs and enable them to modulate the activity of different components of the immune response.

Objective: to evaluate the interactions between immune system components of healthy individuals and EVs derived from monocytic and lymphoid lineage cells generated in the presence of baricitinib (BARI) and itacitinib (ITA) and their possible effects.

Methods: EVs were isolated from monocytes (M) and lymphocytes (L) of healthy individuals, as well as from U937 (U) and Jurkat (J) cells exposed to non-cytotoxic concentrations of BARI, ITA, and dimethyl sulfoxide (DMSO; vehicle control). The binding to and engulfment of EVs by peripheral blood leukocytes of healthy individuals were analyzed by flow cytometry using CFSE-stained EVs and anti-CD45-PeCy7 mAb-labeled whole blood. The effect of EVs on respiratory burst, T-cell activation and proliferation, cytokine synthesis, and platelet aggregation was evaluated. Respiratory burst was assessed in PMA-stimulated neutrophils by the dihydrorhodamine (DHR) test and flow cytometry. T-cell activation and proliferation and cytokine production were assessed in CFSE-stained PBMC cultures stimulated with PHA; expression of the T-cell activation markers CD25 and CD69 and T-cell proliferation were analyzed by flow cytometry, and the cytokine levels were quantified in culture supernatants by Luminex assays. Platelet aggregation was analyzed in platelet-rich plasma (PRP) samples by light transmission aggregometry. The EVs' fatty acid (FA) profile was analyzed using methyl ester derivatization followed by gas chromatography.

Results: ITA exposure during the generation of EVs modified the size of the EVs released; however, treatment with DMSO and BARI did not alter the size of EVs generated from U937 and Jurkat cells. Circulating neutrophils, lymphocytes, and monocytes showed a 2-fold greater tendency to internalize ITA-U-EVs than their respective DMSO control. The neutrophil respiratory burst was attenuated in greater extent by M-EVs than by L-EVs. Autologous ITA--EVs reduced T-cell proliferation by decreasing IL-2 levels and CD25 expression independently of CD69. A higher accumulation of pro-inflammatory cytokines was observed in PHA-stimulated PBMC cultures exposed to M-EVs than to L-EVs; this difference may be related to the higher myristate content of M-EVs. Platelet aggregation increased in the presence of ITA-L/M-EVs by a mechanism presumably dependent on the high arachidonic acid content of the vesicles.

Conclusions: Cellular origin and jakinib exposure modify the FA profile of EVs, enabling them, in turn, to modulate neutrophil respiratory burst, T-cell proliferation, and platelet aggregation. The increased T-cell proliferation induced by BARI-L/M-EVs could explain the lymphocytosis observed in patients treated with BARI. The higher proportion of arachidonic acid in the FA content of ITA-L/M-EVs could be related to the thrombosis described in patients treated with ITA. EVs also induced a decrease in the respiratory burst of neutrophils.

References

Banerjee S, Biehl A, Gadina M, Hasni S, Schwartz D . JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects. Drugs. 2017; 77(5):521-546. PMC: 7102286. DOI: 10.1007/s40265-017-0701-9. View

Fernandez-Botran R . Soluble cytokine receptors: basic immunology and clinical applications. Crit Rev Clin Lab Sci. 1999; 36(3):165-224. DOI: 10.1080/10408369991239196. View

Thomas S, Snowden J, Zeidler M, Danson S . The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours. Br J Cancer. 2015; 113(3):365-71. PMC: 4522639. DOI: 10.1038/bjc.2015.233. View

Fond A, Ravichandran K . Clearance of Dying Cells by Phagocytes: Mechanisms and Implications for Disease Pathogenesis. Adv Exp Med Biol. 2016; 930:25-49. PMC: 6721615. DOI: 10.1007/978-3-319-39406-0_2. View

Saffaryazdi A, Ganjeali A, Farhoosh R, Cheniany M . Variation in phenolic compounds, -linolenic acid and linoleic acid contents and antioxidant activity of purslane ( L.) during phenological growth stages. Physiol Mol Biol Plants. 2020; 26(7):1519-1529. PMC: 7326857. DOI: 10.1007/s12298-020-00836-9. View

Puhm F, Boilard E, Machlus K . Platelet Extracellular Vesicles: Beyond the Blood. Arterioscler Thromb Vasc Biol. 2020; 41(1):87-96. PMC: 7769913. DOI: 10.1161/ATVBAHA.120.314644. View

Holopainen M, Colas R, Valkonen S, Tigistu-Sahle F, Hyvarinen K, Mazzacuva F . Polyunsaturated fatty acids modify the extracellular vesicle membranes and increase the production of proresolving lipid mediators of human mesenchymal stromal cells. Biochim Biophys Acta Mol Cell Biol Lipids. 2019; 1864(10):1350-1362. DOI: 10.1016/j.bbalip.2019.06.010. View

Kuhns D, Long Priel D, Chu J, Zarember K . Isolation and Functional Analysis of Human Neutrophils. Curr Protoc Immunol. 2015; 111:7.23.1-7.23.16. PMC: 4668800. DOI: 10.1002/0471142735.im0723s111. View

Gorjao R, Cury-Boaventura M, de Lima T, Curi R . Regulation of human lymphocyte proliferation by fatty acids. Cell Biochem Funct. 2007; 25(3):305-15. DOI: 10.1002/cbf.1388. View

10.

Bissonnette R, Luchi M, Fidelus-Gort R, Jackson S, Zhang H, Flores R . A randomized, double-blind, placebo-controlled, dose-escalation study of the safety and efficacy of INCB039110, an oral janus kinase 1 inhibitor, in patients with stable, chronic plaque psoriasis. J Dermatolog Treat. 2016; 27(4):332-8. DOI: 10.3109/09546634.2015.1115819. View

11.

Sum E, Rapp M, Durr H, Mazumdar A, Romero P, Trumpfheller C . The tumor-targeted CD40 agonist CEA-CD40 promotes T cell priming via a dual mode of action by increasing antigen delivery to dendritic cells and enhancing their activation. J Immunother Cancer. 2022; 10(3). PMC: 8928381. DOI: 10.1136/jitc-2021-003264. View

12.

Morrison W, Smith L . PREPARATION OF FATTY ACID METHYL ESTERS AND DIMETHYLACETALS FROM LIPIDS WITH BORON FLUORIDE--METHANOL. J Lipid Res. 1964; 5:600-8. View

13.

Kwok Z, Wang C, Jin Y . Extracellular Vesicle Transportation and Uptake by Recipient Cells: A Critical Process to Regulate Human Diseases. Processes (Basel). 2021; 9(2). PMC: 8323758. DOI: 10.3390/pr9020273. View

14.

Kolowos W, Gaipl U, Sheriff A, Voll R, Heyder P, Kern P . Microparticles shed from different antigen-presenting cells display an individual pattern of surface molecules and a distinct potential of allogeneic T-cell activation. Scand J Immunol. 2005; 61(3):226-33. DOI: 10.1111/j.1365-3083.2005.01551.x. View

15.

BLIGH E, Dyer W . A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959; 37(8):911-7. DOI: 10.1139/o59-099. View

16.

Banerjee M, Whiteheart S . The ins and outs of endocytic trafficking in platelet functions. Curr Opin Hematol. 2017; 24(5):467-474. PMC: 5637548. DOI: 10.1097/MOH.0000000000000366. View

17.

Castano D, Garcia L, Rojas M . Increased frequency and cell death of CD16+ monocytes with Mycobacterium tuberculosis infection. Tuberculosis (Edinb). 2011; 91(5):348-60. DOI: 10.1016/j.tube.2011.04.002. View

18.

Koride S, Nayak S, Banfield C, Peterson M . Evaluating the Role of Janus Kinase Pathways in Platelet Homeostasis Using a Systems Modeling Approach. CPT Pharmacometrics Syst Pharmacol. 2019; 8(7):478-488. PMC: 6656939. DOI: 10.1002/psp4.12419. View

19.

Mascarenhas J, Talpaz M, Gupta V, Foltz L, Savona M, Paquette R . Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis. Haematologica. 2016; 102(2):327-335. PMC: 5286940. DOI: 10.3324/haematol.2016.151126. View

20.

Kubo S, Nakayamada S, Sakata K, Kitanaga Y, Ma X, Lee S . Janus Kinase Inhibitor Baricitinib Modulates Human Innate and Adaptive Immune System. Front Immunol. 2018; 9:1510. PMC: 6031708. DOI: 10.3389/fimmu.2018.01510. View